Literature DB >> 10574997

Mammalian HSP60 is a major target for an immunosuppressant mizoribine.

H Itoh1, A Komatsuda, H Wakui, A B Miura, Y Tashima.   

Abstract

It has been reported that immunosuppressant cyclosporin A or FK506 binds to immunophilins in the cell and that these immunophilins make a complex with molecular chaperones HSP70 or HSP90. Although mizoribine has been used clinically as an immunosuppressant, immunophilins of the agent have not yet been fully understood. We investigated their specific binding proteins using mizoribine affinity column chromatography and porcine kidney cytosols. By increasing mizoribine in the eluant from the column, two major proteins (with molecular masses of 60 and 43 kDa) were detected by SDS-polyacrylamide gel electrophoresis. Based on the amino acid sequence analysis of these proteins, 60- and 43-kDa mizoribine-binding proteins were identified with HSP60 and cytosolic actin, respectively. A considerable amount of actin was also eluted from the affinity column by nucleotides, but a very low quantity of HSP60 was eluted under the same conditions. On the other hand, HSP60 was eluted as a major protein in the eluant that was eluted preferentially, with nucleotide followed by mizoribine. Actin was also detected in the eluant, but the quantity of the protein was very low. These results indicated that HSP60 has high affinity to mizoribine, and the interaction was also observed on surface plasmon resonance analysis. Although HSP60 or GroE facilitated refolding of citrate synthase in vitro, mizoribine interfered with the chaperone activity of HSP60. On different types of mizoribine affinity columns, HSP60 or actin recognized the NH(2) group of mizoribine, and this group may be a functional group of the agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574997     DOI: 10.1074/jbc.274.49.35147

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis.

Authors:  Kristoffer R Brandvold; Richard I Morimoto
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

Review 2.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

Review 3.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

4.  Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.

Authors:  Y Imamura; M S Kurokawa; H Yoshikawa; K Nara; E Takada; C Masuda; S Tsukikawa; S Ozaki; T Matsuda; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 5.  Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Authors:  Michael W Graner; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

6.  Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity.

Authors:  Yoko Nagumo; Hideaki Kakeya; Mitsuru Shoji; Yujiro Hayashi; Naoshi Dohmae; Hiroyuki Osada
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

7.  Efficacy of mizoribine and prednisolone combination therapy in adult patients with IgA vasculitis.

Authors:  Akira Mima
Journal:  Rheumatol Int       Date:  2017-03-02       Impact factor: 2.631

8.  Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis.

Authors:  Hikaru Sugimoto; Shiho Matsuno; Noriko Yamanaka; Wako Yumura; Mitsuyo Itabashi; Takashi Takei
Journal:  CEN Case Rep       Date:  2020-08-04

9.  Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy.

Authors:  Yohei Ikezumi; Toshiaki Suzuki; Tamaki Karasawa; Hiroshi Kawachi; David J Nikolic-Paterson; Makoto Uchiyama
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.